Immunesensor Therapeutics Inc.
Clinical trials sponsored by Immunesensor Therapeutics Inc., explained in plain language.
-
Cancer combo trial halted early: what we know
Disease control TerminatedThis phase 2 trial tested whether adding an experimental drug called IMSA101 to standard immunotherapy and a special type of radiation (PULSAR) could help control cancer in people with solid tumors that had started to grow again after prior treatment. Only 16 patients were enroll…
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental combo therapy for advanced cancer shows promise but trial ends early
Disease control TerminatedThis study tested a new treatment for people with non-small cell lung cancer or kidney cancer that had spread to up to six spots in the body. The treatment combined a special type of radiation therapy (PULSAR) with immunotherapy drugs (pembrolizumab or nivolumab), with or without…
Phase: PHASE2 • Sponsor: ImmuneSensor Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC